Head-to-head evidence
Fluticasone propionate/salmeterol (Advair HFA) vs Proventil
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Asthma
Shared mechanism: Beta-2 adrenergic receptor · full Asthma pipeline
Fluticasone propionate/salmeterol (Advair HFA)
Marketed by GlaxoSmithKline
NCT00158834 · Phase 3 · completed
The study randomized 200 children and used double blinding with an active fluticasone comparator. Its primary endpoint was the clinical measure of asthma symptom-free days, but no results are posted, so whether that endpoint was met cannot be determined.
Proventil
Marketed by Amphastar Pharmaceuticals, Inc.
NCT00577655 · Phase 3 · completed
The trial randomized 103 children to albuterol or placebo and masked participants, caregivers, investigators, and outcome assessors. Its primary measures were physiologic lung-function outcomes rather than hard clinical outcomes; the FEV1 comparison was statistically significant, while the PEF comparison was not significant at the prespecified threshold, so the findings were mixed.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Fluticasone propionate/salmeterol (Advair HFA)'s landscape · Proventil's landscape